Home         Forums  

Go Back   Marrowforums > Bone Marrow Failure Diseases > MDS
Register FAQ Search Today's Posts Mark Forums Read

MDS Myelodysplastic syndromes

Reply
 
Thread Tools Search this Thread
  #1  
Old Tue Apr 15, 2008, 04:52 AM
Birgitta-A Birgitta-A is offline
Member
 
Join Date: Oct 2007
Location: Stockholm, Sweden
Posts: 1,918
Thumbs up Targeted therapy with MGCD0103?

Hi all,
The reseachers continue to look for signs that show which patients that will respond to the different drugs for MDS. Now they found a factor, Thrombospondin, that is upregulated in patients (only 2 patients so far) with clinical response on MGCD0103:

"2008 AACR, April 12-16, 2008
Abstract Number: 739
Induction of an anti-angiogenesis factor, Thrombospondin 1 (TSP-1), by a novel histone deacetylase inhibitor, MGCD0103, in human cancer cells in vitro and in vivo
Jianhong Liu, Claire Bonfils, Marja Dubay, Hannah Nguyen, Guillermo Garcia-Manero, Allen S. Yang, Selina Luger, Robert Martell, Jeffrey M. Besterman, Zuomei Li. MethylGene, Inc., Montréal, QC, Canada, MD Anderson Cancer Center, Houston, TX, Norris Comprehensive Cancer Center, Los Angeles, CA, Abramson Cancer Center, Philadelphia, PA

MGCD0103 is a novel non-hydroxamate histone deacetylase inhibitor which specifically targets HDAC1, 2, 3 and 11. Previously, we have shown that MGCD0103 has broad-spectrum antitumor activities in preclinical animal models and its preliminary clinical activity has been shown in multiple Phase II trials in patients with relapsed or refractory Hodgkin’s lymphoma or Non-Hodgkin lymphoma , high-risk myelodysplastic syndrome (MDS) and acute myologenous leukemia (AML)…

…Microarray analysis of peripheral blood mononuclear cells or bone marrow mononuclear cells from five AML patients, who were treated with MGCD0103 either alone or in combination with Vidaza, revealed that the upregulation of expression of TSP-1 in patients with clinical response (n=2) but not in those without response (n=3)…

…The utility of TSP-1 expression as a potential biomarker of MGCD0103 in clinical trials will be discussed."
Kind regards
Birgitta-A
Reply With Quote
Reply


Thread Tools Search this Thread
Search this Thread:

Advanced Search

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

vB code is On
Smilies are On
[IMG] code is On
HTML code is Off
Forum Jump

Similar Threads
Thread Thread Starter Forum Replies Last Post
AYURVEDA CURES LEUKEMIA and MDS Vaidyan Alternative Treatments 84 Thu Aug 2, 2018 09:02 AM
Promacta Receives Breakthrough Therapy Status in the United States Marrowforums News and Events 1 Thu Feb 6, 2014 02:48 PM
Vidaza as Consolidation therapy Joseph Questions and Answers 11 Thu Apr 18, 2013 07:24 AM
What is the case FOR drug therapy?? GaryV Drugs and Drug Treatments 11 Thu Nov 4, 2010 08:37 PM
Type I diabetes and Vidaza therapy alicia91 Tell Your Story 4 Tue Sep 28, 2010 09:11 AM


All times are GMT -4. The time now is 02:00 AM.


Powered by vBulletin® Version 3.6.7
Copyright ©2000 - 2020, Jelsoft Enterprises Ltd.
Forum sites may contain non-authoritative and unverified information.
Medical decisions should be made in consultation with qualified medical professionals.
Site contents exclusive of member posts Copyright © 2006-2020 Marrowforums.org